

Crystal L Mackall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/633199/publications.pdf>

Version: 2024-02-01

143
papers

21,821
citations

28274

55
h-index

19190

118
g-index

153
all docs

153
docs citations

153
times ranked

20474
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 31.e1-31.e9.	1.2	8
2	Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 1961-1968.	5.2	47
3	Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. <i>Blood Advances</i> , 2022, 6, 600-610.	5.2	32
4	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. <i>European Journal of Cancer</i> , 2022, 160, 112-133.	2.8	24
5	GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. <i>Cancer Cell</i> , 2022, 40, 53-69.e9.	16.8	60
6	Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. <i>Nature Medicine</i> , 2022, 28, 333-344.	30.7	105
7	GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. <i>Nature</i> , 2022, 603, 934-941.	27.8	339
8	Neurotoxicity following CD19/CD28 CAR T-cells in children and young adults with B-cell malignancies. <i>Neuro-Oncology</i> , 2022, 24, 1584-1597.	1.2	12
9	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. <i>Journal of Clinical Oncology</i> , 2022, 40, 945-955.	1.6	79
10	YIA22-001: Development of hKIT Chimeric Antigen Receptor T-Cells as Dual Hematopoietic Stem Cell Transplantation Conditioning and Immunotherapeutic Agents for Cure of Pediatric Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, YIA22-001.	4.9	0
11	Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. <i>Science Advances</i> , 2022, 8, eabn8264.	10.3	80
12	Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. <i>Cell</i> , 2022, 185, 1745-1763.e22.	28.9	88
13	Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. , 2022, 10, e004483.		21
14	Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel. <i>Journal of Clinical Oncology</i> , 2022, 40, 10016-10016.	1.6	0
15	Abstract CT142: GD2.Ox40.CD28.z CAR T cell trial in neuroblastoma and osteosarcoma. <i>Cancer Research</i> , 2022, 82, CT142-CT142.	0.9	1
16	Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET. <i>Clinical Cancer Research</i> , 2021, 27, 1058-1068.	7.0	53
17	Frontiers in cancer immunotherapy—a symposium report. <i>Annals of the New York Academy of Sciences</i> , 2021, 1489, 30-47.	3.8	39
18	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2321-2325.	1.4	51

#	ARTICLE	IF	CITATIONS
19	Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 143-155.	5.2	92
20	Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. <i>Immunity</i> , 2021, 54, 586-602.e8.	14.3	80
21	Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. <i>Science</i> , 2021, 372, .	12.6	297
22	Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. <i>Journal of Clinical Oncology</i> , 2021, 39, 1650-1659.	1.6	173
23	EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG. <i>Neuro-Oncology</i> , 2021, 23, i49-i50.	1.2	6
24	Dynamic chromatin regulatory landscape of human CAR T cell exhaustion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	36
25	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1419-1431.	30.7	273
26	Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas. , 2021, , .		7
27	A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 932.e1-932.e11.	1.2	18
28	Abstract 61: Transient "rest" reinvigorates exhausted CAR T cells via epigenetic remodeling. , 2021, , .		1
29	Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming. <i>Clinical Cancer Research</i> , 2021, 27, 6054-6064.	7.0	23
30	Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. <i>Blood</i> , 2021, 138, 2138-2142.	1.4	5
31	Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3034-3043.	1.6	76
32	NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity. <i>Blood Cancer Discovery</i> , 2021, 2, 648-665.	5.0	37
33	Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. <i>Blood Advances</i> , 2021, 5, 5312-5322.	5.2	24
34	Gene editing to enhance the efficacy of cancer cell therapies. <i>Molecular Therapy</i> , 2021, 29, 3153-3162.	8.2	5
35	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 741-741.	1.4	4
36	Immune receptor inhibition through enforced phosphatase recruitment. <i>Nature</i> , 2020, 586, 779-784.	27.8	59

#	ARTICLE	IF	CITATIONS
37	PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors. <i>Cancer Research</i> , 2020, 80, 4731-4740.	0.9	24
38	Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals. <i>Nature Methods</i> , 2020, 17, 852-860.	19.0	123
39	Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report. , 2020, 8, e001073.		2
40	Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. , 2020, 8, e001159.		55
41	Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model. <i>Oncotarget</i> , 2020, 11, 1757360.	4.6	46
42	Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADV1412): a multicentre, open-label, single-arm, phase 1–2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 541-550.	10.7	202
43	Tuning the Antigen Density Requirement for CAR T-cell Activity. <i>Cancer Discovery</i> , 2020, 10, 702-723.	9.4	296
44	Immune-Based Approaches for the Treatment of Pediatric Malignancies. <i>Annual Review of Cancer Biology</i> , 2020, 4, 353-370.	4.5	7
45	Disease detection methodologies in relapsed B–cell acute lymphoblastic leukemia: Opportunities for improvement. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28149.	1.5	11
46	The Emerging Landscape of Immune Cell Therapies. <i>Cell</i> , 2020, 181, 46-62.	28.9	247
47	Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. <i>Nature Medicine</i> , 2020, 26, 712-719.	30.7	172
48	CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1938-1950.	1.6	273
49	Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release. <i>Blood</i> , 2020, 136, 42-44.	1.4	8
50	CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering. <i>Blood</i> , 2020, 136, 53-54.	1.4	28
51	Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA). <i>Blood</i> , 2020, 136, 49-50.	1.4	3
52	Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting. <i>Blood</i> , 2020, 136, 22-22.	1.4	0
53	Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity. <i>Blood</i> , 2020, 136, 32-33.	1.4	4
54	Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. , 2019, 7, 276.		101

#	ARTICLE	IF	CITATIONS
55	Clinical lessons learned from the first leg of the CAR T cell journey. <i>Nature Medicine</i> , 2019, 25, 1341-1355.	30.7	400
56	Driving CAR T cell translation forward. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	61
57	Pharmacologic control of CAR-T cell function using dasatinib. <i>Blood Advances</i> , 2019, 3, 711-717.	5.2	143
58	c-Jun overexpression in CAR T cells induces exhaustion resistance. <i>Nature</i> , 2019, 576, 293-300.	27.8	480
59	CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2560-2574.	7.0	369
60	CAR T cell therapy: inroads to response and resistance. <i>Nature Reviews Immunology</i> , 2019, 19, 73-74.	22.7	148
61	Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy. <i>Blood</i> , 2019, 134, 550-550.	1.4	13
62	Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 744-744.	1.4	42
63	Infectious Complications Associated with CAR T-Cell Therapy. <i>Blood</i> , 2019, 134, 4449-4449.	1.4	6
64	Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 884-884.	1.4	13
65	Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7552-7552.	1.6	5
66	Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming. <i>Blood</i> , 2019, 134, 867-867.	1.4	5
67	Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction. <i>Blood</i> , 2019, 134, 4471-4471.	1.4	0
68	Engineering a designer immunotherapy. <i>Science</i> , 2018, 359, 990-991.	12.6	11
69	Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. <i>Nature Medicine</i> , 2018, 24, 572-579.	30.7	321
70	Neurotoxicity Associated with a High-Affinity GD2 CAR Letter. <i>Cancer Immunology Research</i> , 2018, 6, 494-495.	3.4	21
71	Fludarabine and neurotoxicity in engineered T-cell therapy. <i>Gene Therapy</i> , 2018, 25, 176-191.	4.5	54
72	Tumor Antigen Escape from CAR T-cell Therapy. <i>Cancer Discovery</i> , 2018, 8, 1219-1226.	9.4	661

#	ARTICLE	IF	CITATIONS
73	CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. <i>Nature Medicine</i> , 2018, 24, 20-28.	30.7	1,030
74	Programming CAR-T cells to kill cancer. <i>Nature Biomedical Engineering</i> , 2018, 2, 377-391.	22.5	267
75	Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. <i>Cancer Discovery</i> , 2018, 8, 944-957.	9.4	313
76	Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies. <i>Blood</i> , 2018, 132, 490-490.	1.4	43
77	Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 576-576.	1.4	4
78	Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains. <i>Blood</i> , 2018, 132, 963-963.	1.4	10
79	Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2018, 132, 898-898.	1.4	40
80	Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy. <i>Blood</i> , 2018, 132, 4656-4656.	1.4	11
81	Phase II study of epacadostat with pembrolizumab in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS191-TPS191.	1.6	1
82	Autologous lymphapheresis for the production of chimeric antigen receptor T cells. <i>Transfusion</i> , 2017, 57, 1133-1141.	1.6	110
83	Assessment of programmed death ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. <i>Cancer</i> , 2017, 123, 3807-3815.	4.1	135
84	Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. <i>Cancer Cell</i> , 2017, 31, 476-485.	16.8	116
85	Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. <i>Cancer Cell</i> , 2017, 32, 295-309.e12.	16.8	148
86	Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. <i>Molecular Therapy</i> , 2017, 25, 2189-2201.	8.2	264
87	ADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumorsâA COG study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10526-10526.	1.6	26
88	Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1 c259T in HLA-A2+ patients with synovial sarcoma (NCT01343043).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3000-3000.	1.6	20
89	A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2596-TPS2596.	1.6	13
90	Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. <i>Cancer Genetics</i> , 2016, 209, 182-194.	0.4	38

#	ARTICLE	IF	CITATIONS
91	Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. <i>Cytherapy</i> , 2016, 18, 893-901.	0.7	104
92	Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. <i>Cancer Immunology Research</i> , 2016, 4, 869-880.	3.4	258
93	Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2149-2154.	2.0	42
94	Neuroblastoma. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16078.	30.5	907
95	CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. <i>Nature Communications</i> , 2016, 7, 12320.	12.8	325
96	Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2016, 22, 3643-3650.	7.0	23
97	Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas. <i>Clinical Cancer Research</i> , 2016, 22, 3182-3191.	7.0	109
98	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 1364-1370.	7.0	251
99	A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy. <i>Blood</i> , 2016, 128, 1625-1625.	1.4	10
100	Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 218-218.	1.4	98
101	Tocilizumab-Refractory Cytokine Release Syndrome (CRS) Triggered By Chimeric Antigen Receptor (CAR)-Transduced T Cells May Have Distinct Cytokine Profiles Compared to Typical CRS. <i>Blood</i> , 2016, 128, 3358-3358.	1.4	22
102	Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2016, 128, 650-650.	1.4	34
103	Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. <i>Blood</i> , 2015, 125, 784-792.	1.4	200
104	Chimeric Antigen Receptors for Cancer: Progress and Challenges. <i>Current Stem Cell Reports</i> , 2015, 1, 187-196.	1.6	0
105	4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. <i>Nature Medicine</i> , 2015, 21, 581-590.	30.7	1,304
106	Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. <i>Cancer Discovery</i> , 2015, 5, 1282-1295.	9.4	997
107	T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. <i>Lancet</i> , 2015, 385, 517-528.	13.7	2,476
108	Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 1324-1324.	1.4	21

#	ARTICLE	IF	CITATIONS
109	Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 684-684.	1.4	35
110	Emerging Immunotherapies for Cancer and Their Potential for Application in Pediatric Oncology. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 315-327.	0.4	2
111	Myeloid Cells in Peripheral Blood Mononuclear Cell (PMBC) Concentrates Inhibit the Expansion of Chimeric Antigen Receptor (CAR) T Cells. <i>Blood</i> , 2015, 126, 383-383.	1.4	1
112	Latest in Clinical Application of CAR Cell Therapy for B-cell Malignancy and Transplantation. <i>Blood</i> , 2015, 126, SCI-24-SCI-24.	1.4	0
113	Bioinformatic Description of Immunotherapy Targets for Pediatric T-Cell Leukemia and the Impact of Normal Gene Sets Used for Comparison. <i>Frontiers in Oncology</i> , 2014, 4, 134.	2.8	13
114	Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy. <i>Science Translational Medicine</i> , 2014, 6, 237ra67.	12.4	579
115	Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood</i> , 2014, 124, 188-195.	1.4	2,080
116	Immune-based therapies for childhood cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 693-703.	27.6	84
117	Anti-CD22 chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2013, 121, 1165-1174.	1.4	478
118	The T Cell Receptor As An Oncogene: Thymic Expression Of Self-Reactive T Cell Receptors Targeting Survivin Induces T-Cell Lymphoblastic Leukmia. <i>Blood</i> , 2013, 122, 167-167.	1.4	0
119	Synthetic Chimeric Antigen Receptors (CARs) Rapidly Induce Exhaustion and Augmented Glycolytic Metabolism In Human T Cells and Implicate Persistent CD28 Signaling As a Driver Of Exhaustion In Human T Cells. <i>Blood</i> , 2013, 122, 192-192.	1.4	2
120	Harnessing the biology of IL-7 for therapeutic application. <i>Nature Reviews Immunology</i> , 2011, 11, 330-342.	22.7	490
121	Reply to "IL-7 from dendritic cells essential for the homeostasis of CD4+ T cells". <i>Nature Immunology</i> , 2010, 11, 548-548.	14.5	0
122	Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. <i>Blood</i> , 2009, 114, 3831-3840.	1.4	58
123	A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas. <i>Clinical Cancer Research</i> , 2008, 14, 4850-4858.	7.0	142
124	Depletion of CD25+ T cells and IL-7 administration enhanced anti-tumor effects in mice with B16 melanoma. <i>FASEB Journal</i> , 2008, 22, 1077.15.	0.5	0
125	GVHD Abrogates T Cell Responses to Dendritic Cell Vaccines but Not Vaccine-Induced Proliferation.. <i>Blood</i> , 2007, 110, 1802-1802.	1.4	0
126	Loss of IFN γ R1 Signaling on Donor Bone Marrow Abrogates GVHD but Maintains Immunocompetence.. <i>Blood</i> , 2007, 110, 2180-2180.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Interleukin-7 Produced by Antigen Presenting Cells Regulates the Homeostatic Peripheral Expansion of Naive CD4 T Cells.. Blood, 2007, 110, 1333-1333.	1.4	0
128	Elevated Serum Interleukin-7 Levels Precede the Development of Acute Graft-Versus-Host Disease.. Blood, 2007, 110, 1064-1064.	1.4	8
129	Early Recovery of Thymus-Derived Naïve T Cells in Pediatric Patients (pts) Treated with Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (NMSCCT) for Cancer.. Blood, 2006, 108, 310-310.	1.4	0
130	Effectiveness of chemotherapy in non-rhabdomyosarcoma soft tissue sarcomas-response. Pediatric Blood and Cancer, 2005, 45, 228-228.	1.5	0
131	The Many Faces of IL-7: From Lymphopoiesis to Peripheral T Cell Maintenance. Journal of Immunology, 2005, 174, 6571-6576.	0.8	509
132	Two Categories of Biologic Effects Induced by IL-7 on Human T Cells.. Blood, 2005, 106, 3303-3303.	1.4	0
133	Evaluation of the CD8+ Tumor Associated vs. Non-Tumor Associated Immune Repertoire in Cancer Patients Following Induction of Lymphopenia and Following CD3/4-1BB Based Expansion.. Blood, 2005, 106, 2390-2390.	1.4	0
134	Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (SCT) with Pre-Transplant Targeted Immune Depletion Results in Rapid Full Donor Engraftment in Pediatric Patients with Malignancy.. Blood, 2005, 106, 3672-3672.	1.4	0
135	Subclinical GVHD Impairs Responses to Dendritic Cell Vaccines Following Allogeneic Transplantation.. Blood, 2005, 106, 571-571.	1.4	0
136	Interleukin-7 Over-Expression Regulates T Cell Versus B Cell Lineage Development in the Thymus.. Blood, 2004, 104, 3238-3238.	1.4	0
137	Focus on sarcomas. Cancer Cell, 2002, 2, 175-178.	16.8	89
138	Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines. Journal of Clinical Oncology, 2001, 19, 1848-1854.	1.6	113
139	T-Cell Immunodeficiency Following Cytotoxic Antineoplastic Therapy: A Review. Stem Cells, 2000, 18, 10-18.	3.2	182
140	Targeting pediatric malignancies for T cell-mediated immune responses. Current Oncology Reports, 2000, 2, 539-546.	4.0	3
141	T-Cell Immunodeficiency Following Cytotoxic Antineoplastic Therapy: A Review. Oncologist, 1999, 4, 370-378.	3.7	37
142	Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunological Reviews, 1997, 157, 61-72.	6.0	218
143	Constraints on CD4 Recovery Postchemotherapy in Adults: Thymic Insufficiency and Apoptotic Decline of Expanded Peripheral CD4 Cells. Blood, 1997, 90, 3789-3798.	1.4	300